Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW 2217, Sydney, Australia.
J Gastrointest Surg. 2010 Sep;14(9):1442-52. doi: 10.1007/s11605-009-1129-7. Epub 2010 Apr 9.
This systematic review objectively evaluates the safety and outcomes of extended pancreaticoduodenectomy with vascular resection for pancreatic cancer involving critical adjacent vessels namely the superior mesenteric-portal veins, hepatic artery, superior mesenteric artery, and celiac axis.
Electronic searches were performed on two databases from January 1995 to August 2009. The end points were: firstly, to evaluate the safety through reporting the mortality rate and associated complications and, secondly, the outcome by reporting the survival after surgery. This was synthesized through a narrative review with full tabulation of results of all included studies.
Twenty-eight retrospective studies comprising of 1,458 patients were reviewed. Vein thrombosis and arterial involvement were reported as contraindications to surgery in 62% and 71% of studies, respectively. The median mortality rate was 4% (range, 0% to 17%). The median R0 and R1 rates were 75% (range, 14% to 100%) and 25% (range, 0% to 86%), respectively. In high volume centers, the median survival was 15 months (range, 9 to 23 months). Nine of 10 (90%) studies comparing the survival after extended pancreaticoduodenectomy with vascular resection versus standard pancreaticoduodenectomy reported statistically similar (p > 0.05) survival outcomes. Undertaking vascular resection was not associated with a poorer survival.
The morbidity, mortality, and survival outcome after undertaking extended pancreaticoduodenectomy with vascular resection for pancreatic cancer with venous involvement and/or limited arterial involvement is acceptable in the setting of an expert referral center and should not be a contraindication to a curative surgery.
本系统评价客观评估了伴有临界毗邻血管(肠系膜上静脉-门静脉、肝总动脉、肠系膜上动脉和腹腔动脉)受累的胰腺癌行扩大胰十二指肠切除术联合血管切除的安全性和疗效。
1995 年 1 月至 2009 年 8 月,我们在两个数据库中进行了电子检索。终点为:首先,通过报告死亡率和相关并发症评估安全性;其次,通过报告术后生存情况评估疗效。我们通过叙述性综述对结果进行综合,全面列出所有纳入研究的结果。
共 28 项回顾性研究纳入了 1458 例患者。62%和 71%的研究分别将静脉血栓形成和动脉受累报告为手术禁忌证。中位死亡率为 4%(范围 0%至 17%)。中位 R0 和 R1 切除率分别为 75%(范围 14%至 100%)和 25%(范围 0%至 86%)。在高容量中心,中位生存时间为 15 个月(范围 9 至 23 个月)。10 项比较扩大胰十二指肠切除术联合血管切除与标准胰十二指肠切除术疗效的研究中,有 9 项(90%)报告了统计学上相似的生存结果(p>0.05)。进行血管切除与生存结果较差无关。
在专家转诊中心,伴有静脉受累和/或有限动脉受累的胰腺癌行扩大胰十二指肠切除术联合血管切除的并发症发生率、死亡率和生存结局是可以接受的,不应作为根治性手术的禁忌证。